Trial Profile
Treatment with bevacizumab and irinotecan in patients with recurrent or refractory high grade glioma after conventional treatment.
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 23 May 2014
Price :
$35
*
At a glance
- Drugs Bevacizumab (Primary) ; Irinotecan (Primary)
- Indications Glioma
- Focus Therapeutic Use
- 23 May 2014 New trial record